| 1 |
34987165 | Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. | 2022 Jan 5 |
2 |
| 2 |
32871991 | Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report. | 2020 Aug 14 |
1 |
| 3 |
31073022 | Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy. | 2019 Aug |
1 |
| 4 |
29317554 | Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. | 2018 Apr |
2 |
| 5 |
27103007 | Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. | 2016 Jun |
1 |
| 6 |
25975443 | Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. | 2015 Jun |
3 |
| 7 |
24951124 | Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. | 2014 Nov |
1 |
| 8 |
21257672 | Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. | 2011 Aug |
1 |